FDA approves gefurulimab for myasthenia gravis - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves gefurulimab for myasthenia gravis

  • By

  • Mouj Hijazi

  • November 16, 2026

  • 3 min

Share

Objective:

The article examines the objective, findings, and clinical context described in FDA approves gefurulimab for myasthenia gravis.

Approach:
  • Approval and mechanism: The FDA approved gefurulimab-gaks (Klygefa), a complement C5 inhibitor, for adults with AChR antibody-positive generalized myasthenia gravis. It is administered subcutaneously once weekly.
  • Evidence: Approval was supported by PREVAIL, a 26-week, randomized, double-blind, placebo-controlled phase 3 trial of 260 adults who continued eligible background therapies at stable doses.
  • Administration and safety requirements: The weight-based regimen begins with a loading dose on day 1, followed by weekly dosing from day 8. The label includes a boxed warning for serious meningococcal infections and requires vaccination and participation in a restricted REMS.
Key Findings:
  • At week 26, MG-ADL scores improved by 4.2 points with gefurulimab and 2.6 points with placebo; the treatment difference was −1.6 points.
  • Quantitative Myasthenia Gravis scores improved by 4.5 points with gefurulimab and 2.4 points with placebo.
  • At least a 3-point MG-ADL improvement occurred in 65.5% of gefurulimab recipients and 52.2% of placebo recipients.
  • Reported adverse events included injection-site reactions (12% vs 3%), back pain (8% vs 2%), and vomiting (5% vs 1%) with gefurulimab versus placebo, respectively.
Interpretation:

The FDA-approved prescribing information identifies change from baseline in MG-ADL score at week 26 as the primary endpoint. AstraZeneca reported that improvements began at week 1 and continued through week 26.

Limitations:
  • The provided context does not report longer-term outcomes beyond the 26-week trial.
  • The provided context does not include detailed results for other safety outcomes.
Conclusion:

Patients or caregivers may administer gefurulimab after appropriate training. The label requires meningococcal vaccination at least 2 weeks before treatment; antibacterial prophylaxis is required when urgent treatment is needed in patients not up to date with vaccination. Treatment must not be initiated during an unresolved serious Neisseria meningitidis infection.

Sources:

Original Source(s)

Related Content